UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Recruitment status Preinitiation
Unique ID issued by UMIN UMIN000014112
Receipt No. R000016428
Scientific Title Pathogenesis of sleep apnea syndrome in patients with hypertension and chronic kidney disease
Date of disclosure of the study information 2014/05/30
Last modified on 2014/05/29

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Pathogenesis of sleep apnea syndrome in patients with hypertension and chronic kidney disease
Acronym Pathogenesis of sleep apnea syndrome in patients with hypertension and chronic kidney disease
Scientific Title Pathogenesis of sleep apnea syndrome in patients with hypertension and chronic kidney disease
Scientific Title:Acronym Pathogenesis of sleep apnea syndrome in patients with hypertension and chronic kidney disease
Region
Japan

Condition
Condition hypertension
chronic kidney disease
Classification by specialty
Nephrology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 The present study aims to elucidate pathogenesis of sleep apnea syndrome in patients with hypertension and chronic kidney disease
Basic objectives2 Others
Basic objectives -Others We follow-up the crinical coarse under existing treatment
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes We distinguish patients with or without sleep apnea syndrome
We compare the clinical coarse
Key secondary outcomes

In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field.

Base
Study type

Study design
Basic design Parallel
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine Device,equipment Behavior,custom
Interventions/Control_1 sleep apnea syndrome(+)
Interventions/Control_2 sleep apnea syndrome(-)
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required.

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria patients with hypertension and chronic kidney disease
Key exclusion criteria unsuitable case for this study
Target sample size 100

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Suzuki Yusuke
Organization Juntendo Univetsity Faculty of Medicine
Division name Nephrology
Zip code
Address 2-1-1 hongo bunkyoku tokyo
TEL 03-3813-3111
Email yusuke@juntendo.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Takahashi Keiko
Organization Juntendo Univetsity Faculty of Medicine
Division name Nephrology
Zip code
Address 2-1-1 hongo bunkyoku tokyo
TEL 03-3813-3111
Homepage URL
Email keitaka@juntendo.ac.jp

Sponsor
Institute Nephrology, Juntendo Univetsity Faculty of Medicine
Institute
Department

Sponsor means an organization that is responsible for plan, deployment and
report of the research including funding management. It doesn't mean
funding agency". Therefore, all clinical trial should have the one.

Funding Source
Organization Nephrology, Juntendo Univetsity Faculty of Medicine
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2014 Year 05 Month 30 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Preinitiation
Date of protocol fixation
2014 Year 05 Month 23 Day
Date of IRB
Anticipated trial start date
2014 Year 06 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2014 Year 05 Month 29 Day
Last modified on
2014 Year 05 Month 29 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016428


Contact us.